Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis
CL Pawlowski, W Li, M Sun, K Ravichandran… - Biomaterials, 2017 - Elsevier
Intravascular administration of plasminogen activators is a clinically important thrombolytic
strategy to treat occlusive vascular conditions. A major issue with this strategy is the systemic …
strategy to treat occlusive vascular conditions. A major issue with this strategy is the systemic …
An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy
It remains a major challenge to develop a selective and effective fibrinolytic system for
thrombolysis with minimal undesirable side effects. Herein, we report a multifunctional …
thrombolysis with minimal undesirable side effects. Herein, we report a multifunctional …
Bioresponsive polyphenol-based nanoparticles as thrombolytic drug carriers
Thrombolytic (clot-busting) therapies with plasminogen activators (PAs) are first-line
treatments against acute thrombosis and ischemic stroke. However, limitations such as …
treatments against acute thrombosis and ischemic stroke. However, limitations such as …
Nanomedicine progress in thrombolytic therapy
A Zenych, L Fournier, C Chauvierre - Biomaterials, 2020 - Elsevier
Thrombotic occlusions of blood vessels are responsible for life-threatening cardiovascular
disorders such as myocardial infarction, ischemic stroke, and venous thromboembolism …
disorders such as myocardial infarction, ischemic stroke, and venous thromboembolism …
Engineered nanoplatelets for targeted delivery of plasminogen activators to reverse thrombus in multiple mouse thrombosis models
J Xu, Y Zhang, J Xu, G Liu, C Di, X Zhao, X Li… - Advanced …, 2020 - Wiley Online Library
Rapid cut‐off of blood supply in diseases involving thrombosis is a major cause of morbidity
and mortality worldwide. However, the current thrombolysis strategies offer limited results …
and mortality worldwide. However, the current thrombolysis strategies offer limited results …
Platelet-mimicking procoagulant nanoparticles augment hemostasis in animal models of bleeding
Treatment of bleeding disorders using transfusion of donor-derived platelets faces logistical
challenges due to their limited availability, high risk of contamination, and short (5 to 7 days) …
challenges due to their limited availability, high risk of contamination, and short (5 to 7 days) …
[HTML][HTML] Platelet‐inspired nanomedicine in hemostasis thrombosis and thromboinflammation
Platelets are anucleate cell‐fragments derived predominantly from megakaryocytes in the
bone marrow and released in the blood circulation, with a normal count of 150 000–40 000 …
bone marrow and released in the blood circulation, with a normal count of 150 000–40 000 …
Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy
JR McCarthy, IY Sazonova, SS Erdem, T Hara… - …, 2012 - Future Medicine
Background: Current thrombolytic therapies utilize exogenous plasminogen activators (PAs)
to effectively lyse clots, restoring blood flow, and preventing tissue and organ death. These …
to effectively lyse clots, restoring blood flow, and preventing tissue and organ death. These …
Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy
Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …
Novel and emerging therapies: thrombus-targeted fibrinolysis
Thrombolytic therapy by infusion of analogs of tissue plasminogen activator (tPA), other
recombinant-based plasminogen activators (eg, alteplase, reteplase, and tenecteplase) …
recombinant-based plasminogen activators (eg, alteplase, reteplase, and tenecteplase) …